Please join us as we speak to Dr. Daniel Pollyea from the University of Colorado School of Medicine.  In this episode, Dr. Pollyea discusses the group of diseases that make up Myelodysplastic Syndromes (MDS) and how their variability leads to different treatments and prognoses, from active monitoring to chemotherapy and/or stem cell transplantation.  He shares his excitement about new treatment advances and is looking forward to an era of innovative targeted treatments for MDS.

Mentioned on this episode: 

• Myelodysplastic Syndromes (MDS)
• Myelodysplastic Syndromes (MDS) Booklets
• Acute Myeloid Leukemia (AML)
• Stem Cell Transplant
• IPSS-R Scoring System
• IPSS-M Scoring System
• Clinical Trial Support Center

Additional LLS Support Resources: 

• Information Specialists
• Financial support
• Free telephone/web patient programs 
• Patti Robinson Kaufmann First Connection Program
• Free booklets 
• LLS Public Policy & Advocacy
• Online chats 
• Caregiver support 
• Support groups 
• Free Nutrition Consultations 
• LLS Advocacy
• Survivorship Workbook

Support for this episode provided by Taiho Oncology.

The post Myelodysplastic Syndromes (MDS): A Group of Diseases appeared first on The Bloodline with LLS.